Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;57(5):1063-9.
doi: 10.3349/ymj.2016.57.5.1063.

Dyspnea as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer

Woo Ho Ban  1 , Jong Min Lee  1 , Jick Hwan Ha  1 , Chang Dong Yeo  1 , Hyeon Hui Kang  1 , Chin Kook Rhee  1 , Hwa Sik Moon  1 , Sang Haak Lee  2
Affiliations

Dyspnea as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer

Woo Ho Ban et al. Yonsei Med J. 2016 Sep.

Abstract

Purpose: To investigate associations between dyspnea and clinical outcomes in patients with non-small cell lung cancer (NSCLC).

Materials and methods: From 2001 to 2014, we retrospectively reviewed the prospective lung cancer database of St. Paul's Hospital at the Catholic University of Korea. We enrolled patients with NSCLC and evaluated symptoms of dyspnea using modified Medical Research Council (mMRC) scores. Also, we estimated pulmonary functions and analyzed survival data.

Results: In total, 457 NSCLC patients were enrolled, and 259 (56.7%) had dyspnea. Among those with dyspnea and whose mMRC scores were available (109 patients had no mMRC score), 85 (56.6%) patients had an mMRC score <2, while 65 (43.3%) had an mMRC score ≥2. Significant decreased pulmonary functions were observed in patients with dyspnea. In multivariate analysis, aging, poor performance status, advanced stage, low forced expiratory volume in 1 second (%), and an mMRC score ≥2 were found to be significant prognostic factors for patient survival.

Conclusion: Dyspnea could be a significant prognostic factor in patients with NSCLC.

Keywords: Lung neoplasm; dyspnea; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

Figures

Fig. 1
Fig. 1. Distribution of patients with dyspnea according to modified Medical Research Council (mMRC) scale.
Fig. 2
Fig. 2. Prevalence of chronic obstructive pulmonary disease in patients with dyspnea. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Fig. 3
Fig. 3. Kaplan-Meier survival curve of patients according to dyspnea (A) and modified Medical Research Council (mMRC) scale (B).
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165–1174. - PubMed
    1. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409. - PMC - PubMed
    1. Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax. 2013;68:551–564. - PubMed
    1. Carlson LE, Waller A, Groff SL, Bultz BD. Screening for distress, the sixth vital sign, in lung cancer patients: effects on pain, fatigue, and common problems--secondary outcomes of a randomized controlled trial. Psychooncology. 2013;22:1880–1888. - PubMed